NEW HAVEN, Conn. and KENNESAW, Ga., April 8, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) and FOB Synthesis, Inc. today announced that the companies have signed an exclusive agreement granting Achillion worldwide rights for the research, development and commercialization of certain FOB compounds for the treatment of serious bacterial infections. The licensed carbapenem compounds show excellent activity against a broad spectrum of bacterial isolates, including methicillin-resistant Staphylococcus aureus, or MRSA.
